Morphic Therapeutic is a biopharmaceutical company developing a new generation of oral
integrin therapies for the treatment of serious chronic diseases, including autoimmune, cardiovascular and metabolic diseases, fibrosis and cancer.
Schrodinger technology informs Morphic's
integrin technology, or MInT Platform, which leverages Morphic's unique understanding of
integrin structure and biology to develop a pipeline of novel product candidates designed to achieve the potency, high selectivity, and pharmaceutical properties required for oral administration.
The collaboration is aimed at discovering and developing novel
integrin therapeutics for patients with conditions not adequately addressed by current therapies.
This technique involves developing cells from the Crohn's disease patients with a molecule called RAR568, which restores healthy levels of
integrin EAA4EAA7.
Biotechnology company Morphic Therapeutic said on Thursday that it plans to advance a number of its oral
integrin therapeutics for fibrosis-related indications under a research and development collaboration with AbbVie (NYSE:ABBV) subject to clearance under the Hart-Scott-Rodino Antitrust Improvements Act.
Eisai and EA Pharma are engaged in development of the small molecule compound E6007, as a new IBD treatment with a mechanism of action for inhibiting
integrin activity (Reference document 1), and using an analogue of this E6007 (ER-464195-01), the joint research group utilized a biomarker technology developed by University of Tsukuba which visualizes protein-protein interaction in an attempt to reveal the mechanism expressing anti-inflammatory effects.
[12.] Brower DL, Brower SM, Hayward DC, Ball EE (1997) Molecular evolution of
integrins: genes encoding
integrin beta subunits from a coral and a sponge.
Expression levels of [alpha]v, [alpha]4, [beta]1, and [beta]6
integrin were determined using specific antibodies with flow cytometry on PEO-1 cells.
Focal adhesion (FA) is a specialized structure formed where bundles of actin filaments are anchored to transmembrane receptors of the
integrin family through a complex of adaptor and signaling proteins enabling cells to adhere, spread and migrate (Gilmore & Burridge, 1996).
Leukocyte adhesion deficiency (LAD) is a rare primary immunodeficiency disorder with autosomal recessive inheritance which is characterized by presence of a defect of phagocytic function resulting from a lack of leukocyte cell surface expression of b2
integrin molecules (CD11 and CD18) that are essential for chemotaxis.
Integrin [[alpha].sub.v][[beta].sub.3] is a cell adhesion molecule overexpressed on most tumor cells for regulation of angiogenesis and plays important roles in various stages, such as malignant transformation, tumor growth, progression, invasion, and metastasis [20].
